Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Selicrelumab · CP-870893

Monoclonal antibody · Agonist of CD40 · developed by Hoffmann-La Roche

Phase 1/2 Most advanced trial
1 Registered trials

What is Selicrelumab?

Selicrelumab is a human IgG2 monoclonal antibody agonist of CD40 that binds to CD40 on immune cells and cancer cells, triggering CD40-dependent signaling and activating antigen-presenting cells, B-cells, and T-cells to enhance anti-tumor immune responses. It is studied in metastatic breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CP-870893
Drug type
Monoclonal antibody
Targets
CD40
Mechanism
Agonist of CD40
Pathways
CD40-dependent signaling, immune cell activation
Therapy area
Oncology
Developer
Hoffmann-La Roche
In trials of
GILD
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
0O39RGI33V

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03424005 Phase 1/2 Metastatic Breast Cancer Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Breast Cancer

Other drugs acting on CD40

CDX-1140 Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.